logo-loader
viewAkorn, Inc.

Generic drugs firm Akorn confirms takeover talks with Germany's Fresenius

In separate statements, both companies said there was no certainty the discussions would lead to a deal

Drugs
Illinois-based Akorn – which had sales of US$1.1bn last year - has a current market cap of about US$3.7bn

US generic drugs manufacturer Akorn Inc (NASDAQ:AKRX) has confirmed it is in takeover talks with German healthcare firm Fresenius SE.

In separate statements, both companies said there was no certainty the discussions would lead to a deal.

Illinois-based Akorn – which had sales of US$1.1bn last year  - has a current market cap of about US$3.7bn.

Asthma to heart medicines …

The Nasdaq-listed group makes branded and generic versions of ophthalmic, injectable and non-injectable drugs with manufacturing facilities in the US and outside the country.

Its biggest brand-name drugs include asthma treatment, Xopenex and heart medicine, Akten.

In premarket trading, Akorn shares were over 12% higher at US$33.45 each, having soared 18% higher on Friday having following reports of a bid.

Quick facts: Akorn, Inc.

Price: 1.36 USD

NASDAQ:AKRX
Market: NASDAQ
Market Cap: $171.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator's Stephen Blyth outlines five-year growth plans as core businesses...

Xpediator PLC's (LON:XPD) Stephen Blyth speaks to Proactive London following the release of its 2019 trading update. The firm saw turnover rise 19% to £212mln - boosted by acquisitions and organic growth while adjusted pre-tax profit's expected to be slightly above £5mln. Blyth says a big...

2 days, 17 hours ago

2 min read